OTCMKTS:GMXAY

GENMAB A/S/S Stock Forecast, Price & News

$42.92
-0.61 (-1.40 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$42.80
▼
$44.11
50-Day Range
$18.35
▼
$44.57
52-Week Range
$12.10
▼
$19.00
Volume6.15 million shs
Average Volume48,553 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GMXAY News and Ratings via Email

Sign-up to receive the latest news and ratings for GENMAB A/S/S and its competitors with MarketBeat's FREE daily newsletter.


About GENMAB A/S/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Headlines

GMAB Aug 2021 22.500 put
GMAB Aug 2021 22.500 put
April 26, 2021 |  uk.finance.yahoo.com
Bullish Two Hundred Day Moving Average Cross - GMAB
Bullish Two Hundred Day Moving Average Cross - GMAB
April 22, 2021 |  nasdaq.com
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
March 30, 2021 |  ca.finance.yahoo.com
Genmab: Novartis Gets European Approval For Kesimpta To Treat Relapsing Multiple Sclerosis In Adults
Genmab: Novartis Gets European Approval For Kesimpta To Treat Relapsing Multiple Sclerosis In Adults
March 30, 2021 |  markets.businessinsider.com
Genmab A/S (GMABN.MX)
Genmab A/S (GMABN.MX)
March 22, 2021 |  ca.finance.yahoo.com
Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
March 10, 2021 |  finance.yahoo.com
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call Transcript
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call Transcript
February 25, 2021 |  seekingalpha.com
Genmab A/S: Genmab announces initiation of share buy-back program
Genmab A/S: Genmab announces initiation of share buy-back program
February 24, 2021 |  bloomberg.com
Genmab A-S earnings preview: what Wall Street is expecting
Genmab A-S earnings preview: what Wall Street is expecting
February 21, 2021 |  markets.businessinsider.com
Genmab A-S (spons ADRs) earnings: heres what Wall Street expects
Genmab A-S (spons ADRs) earnings: here's what Wall Street expects
February 21, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.52 out of 5 stars

Medical Sector

1579th out of 2,101 stocks

Biotechnology Industry

39th out of 89 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GENMAB A/S/S (OTCMKTS:GMXAY) Frequently Asked Questions

What stocks does MarketBeat like better than GENMAB A/S/S?

Wall Street analysts have given GENMAB A/S/S a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GENMAB A/S/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has GENMAB A/S/S's stock price been impacted by COVID-19?

GENMAB A/S/S's stock was trading at $23.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GMXAY stock has increased by 82.6% and is now trading at $42.92.
View which stocks have been most impacted by COVID-19.

Who are GENMAB A/S/S's key executives?

GENMAB A/S/S's management team includes the following people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, Pres & CEO (Age 58)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 58)
  • Mr. Peter Storm Kristensen, Associate Director of Legal & Non-Independent Director (Age 44)
  • Mr. Rick Hibbert, Associate Director of Protein Production & Chemistry and Non-Independent Director (Age 39)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)

Who are some of GENMAB A/S/S's key competitors?

Some companies that are related to GENMAB A/S/S include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS) and Amplia Therapeutics (ATX).
View all of GMXAY's competitors.

What is GENMAB A/S/S's stock symbol?

GENMAB A/S/S trades on the OTCMKTS under the ticker symbol "GMXAY."

How do I buy shares of GENMAB A/S/S?

Shares of GMXAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GENMAB A/S/S's stock price today?

One share of GMXAY stock can currently be purchased for approximately $42.92.

How many employees does GENMAB A/S/S have?

GENMAB A/S/S employs 377 workers across the globe.

What is GENMAB A/S/S's official website?

The official website for GENMAB A/S/S is www.genmab.com.

How can I contact GENMAB A/S/S?

The company can be reached via phone at 45 70 20 27 28.


This page was last updated on 6/21/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.